Archive for the 'melanocortin receptors (MCR) subtypes MC1R and MC3R' Category

melanocortin receptors (MCR) subtypes MC1R and MC3R news feed.

Groundbreaking Clinical Trial for Mesothelioma Patients

The researchers and scientists at the Baylor College of Medicine Mesothelioma Treatment Center at Baylor St. Luke’s Medical Center excitedly announced a new clinical trial that combines immunotherapy and surgery for the treatment of mesothelioma. This is the first time that these two treatments have been combined and scientists and researchers are hopeful for positive


Zengen’s new study reviews novel approach to control inflammation using melanocortin receptors; Study supports development potential in several therapeutic areas

WOODLAND HILLS, Calif. Zengen, Inc. announced today that its researchers have discovered that activation of melanocortin receptors (MCR) subtypes MC1R and MC3R could be a novel strategy to control inflammatory disorders. The findings, "Targeting Melanocortin Receptors as a Novel Strategy to Control Inflammation," appear in the March 2004 issue of Pharmacological Reviews, a publication of


Last update: April 01, 2019. 03:30:08 pm.